A retrospective analysis of regorafenib and TAS-102 for advanced or recurrent colorectal cancer

A retrospective analysis of regorafenib and TAS-102 for advanced or recurrent colorectal cancer - RETAS study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024116

Enrollment

Registered

2016-09-21

Start date

2016-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or recurrent colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced or recurrent colorectal cancer patient adminisitered Regorafenib or TAS-102 in periods from March, 2013 to April, 2016 at Sapporo City General Hospital

Exclusion criteria

Exclusion criteria: The case that an image evaluation was never accomplished

Design outcomes

Primary

Measure	Time frame
safety (hematological and non-hematological adverse event)	—

Secondary

Measure	Time frame
Response rate Disease control rate Progression free survival Overall survival	—

Countries

Japan

Contacts

Public ContactMasataka Yagisawa

Sapporo City General Hospital medical office

yagisawa.m@hotmail.co.jp011-726-2211

Outcome results